Skip to main content

Table 1 Predicted reduction in lifetime risk of cancer with the prototype contraceptive

From: Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists

  Duration of regimen (years)
Cancer type 5 10 15
Breast 31% 53% 70%
Endometrium 18% 33% 45%
Ovary 41% 67% 84%
  1. The calculations were made using the model described by Pike [12], and were based on using the regimen at any time after the first full-term pregnancy and before age 40 years.